Antimicrobial beta-peptides and alpha-peptoids

Troels Godballe, Line L. Nilsson, Pernille D. Petersen, Håvard Jenssen

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Resumé

The field of drug discovery and development has seen tremendous activity over the past decade to better tackle the increasing occurrence of drugresistant
bacterial infections and to alleviate some of the pressure we put on the last-resort drugs on the market. One of the new and promising drug candidates is derived from naturally occurring antimicrobial peptides. However, despite promising results in early-stage clinical trials, these molecules have faced some difficulties securing FDA approval, which can be linked to their poor metabolic
stability. Hence, mimetics of these antimicrobial peptides have been suggested as new templates for antibacterial compound design, because these mimetics are resistant against degradation by proteases. This review will discuss the
structural features of two different types of mimetics, b-peptides and a-peptoids, in relation to their antibacterial activity and conclude on their
potential as new candidates for bacterial intervention
OriginalsprogEngelsk
TidsskriftChemical Biology and Drug Design (Print)
Vol/bind77
Udgave nummer2
Sider (fra-til)107-116
ISSN1747-0277
DOI
StatusUdgivet - 2011

Citer dette

Godballe, Troels ; Nilsson, Line L. ; Petersen, Pernille D. ; Jenssen, Håvard. / Antimicrobial beta-peptides and alpha-peptoids. I: Chemical Biology and Drug Design (Print). 2011 ; Bind 77, Nr. 2. s. 107-116.
@article{4994588626b646ccb6e3be217e71ace7,
title = "Antimicrobial beta-peptides and alpha-peptoids",
abstract = "The field of drug discovery and development has seen tremendous activity over the past decade to better tackle the increasing occurrence of drugresistant bacterial infections and to alleviate some of the pressure we put on the last-resort drugs on the market. One of the new and promising drug candidates is derived from naturally occurring antimicrobial peptides. However, despite promising results in early-stage clinical trials, these molecules have faced some difficulties securing FDA approval, which can be linked to their poor metabolic stability. Hence, mimetics of these antimicrobial peptides have been suggested as new templates for antibacterial compound design, because these mimetics are resistant against degradation by proteases. This review will discuss the structural features of two different types of mimetics, b-peptides and a-peptoids, in relation to their antibacterial activity and conclude on their potential as new candidates for bacterial intervention",
keywords = "α-peptoids, antibiotic resistance, antimicrobial peptides, β-peptide, drug design, peptidomimetics",
author = "Troels Godballe and Nilsson, {Line L.} and Petersen, {Pernille D.} and H{\aa}vard Jenssen",
year = "2011",
doi = "10.1111/j.1747-0285.2010.01067.x",
language = "English",
volume = "77",
pages = "107--116",
journal = "Chemical Biology and Drug Design (Print)",
issn = "1747-0277",
publisher = "Wiley-Blackwell Publishing, Inc",
number = "2",

}

Antimicrobial beta-peptides and alpha-peptoids. / Godballe, Troels; Nilsson, Line L. ; Petersen, Pernille D.; Jenssen, Håvard.

I: Chemical Biology and Drug Design (Print), Bind 77, Nr. 2, 2011, s. 107-116.

Publikation: Bidrag til tidsskriftReviewForskningpeer review

TY - JOUR

T1 - Antimicrobial beta-peptides and alpha-peptoids

AU - Godballe, Troels

AU - Nilsson, Line L.

AU - Petersen, Pernille D.

AU - Jenssen, Håvard

PY - 2011

Y1 - 2011

N2 - The field of drug discovery and development has seen tremendous activity over the past decade to better tackle the increasing occurrence of drugresistant bacterial infections and to alleviate some of the pressure we put on the last-resort drugs on the market. One of the new and promising drug candidates is derived from naturally occurring antimicrobial peptides. However, despite promising results in early-stage clinical trials, these molecules have faced some difficulties securing FDA approval, which can be linked to their poor metabolic stability. Hence, mimetics of these antimicrobial peptides have been suggested as new templates for antibacterial compound design, because these mimetics are resistant against degradation by proteases. This review will discuss the structural features of two different types of mimetics, b-peptides and a-peptoids, in relation to their antibacterial activity and conclude on their potential as new candidates for bacterial intervention

AB - The field of drug discovery and development has seen tremendous activity over the past decade to better tackle the increasing occurrence of drugresistant bacterial infections and to alleviate some of the pressure we put on the last-resort drugs on the market. One of the new and promising drug candidates is derived from naturally occurring antimicrobial peptides. However, despite promising results in early-stage clinical trials, these molecules have faced some difficulties securing FDA approval, which can be linked to their poor metabolic stability. Hence, mimetics of these antimicrobial peptides have been suggested as new templates for antibacterial compound design, because these mimetics are resistant against degradation by proteases. This review will discuss the structural features of two different types of mimetics, b-peptides and a-peptoids, in relation to their antibacterial activity and conclude on their potential as new candidates for bacterial intervention

KW - α-peptoids

KW - antibiotic resistance

KW - antimicrobial peptides

KW - β-peptide

KW - drug design

KW - peptidomimetics

U2 - 10.1111/j.1747-0285.2010.01067.x

DO - 10.1111/j.1747-0285.2010.01067.x

M3 - Review

VL - 77

SP - 107

EP - 116

JO - Chemical Biology and Drug Design (Print)

JF - Chemical Biology and Drug Design (Print)

SN - 1747-0277

IS - 2

ER -